Merck has announced the divestment of its biosimilars activities. Fresenius will take over the business and integrate them into Kabi. Merck will receive a €170m upfront payment and up to €500m in royalties. Closing is expected in H2 17.
25 Apr 2017
Back to origins
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Back to origins
Merck KGaA (MRCK:WBO) | 0 0 1.2% | Mkt Cap: 10,792m
- Published:
25 Apr 2017 -
Author:
Martin Schnee -
Pages:
2
Merck has announced the divestment of its biosimilars activities. Fresenius will take over the business and integrate them into Kabi. Merck will receive a €170m upfront payment and up to €500m in royalties. Closing is expected in H2 17.